Annual Live Symposia Series Clinical Updates for Nurse Practitioners & Physician Assistants



LIVE CONFERENCE SERIES





Impacting COPD Care: Addressing Alpha-1 Antitrypsin Deficiency Final Outcome Report for 2 Live Activities Grant ID 3750: • February 4, 2020



Executive Summary

This activity focused on improving the recognition, diagnosis and treatment of Alpha-1 Antitrypsin Deficiency (AATD).

- 771 attendees in multiple professional specialties were reached in this program.
- Improvement across all learning domains was noted ranging from 36% to 406%.
- Overall, the program improved the ability of learners to recognize how to diagnosis and manage AATD.

Persistent Educational Gaps

771 total attendees 2 cities: 245 attendees

- Though improvements were observed, learners demonstrated score slippage on the PCA indicating persistent gaps in the several areas including:
 - Pathophysiology of AAT Deficiency
 - Genetic phenotyping in AATD and its impact on risk for COPD
 - AATD screening strategies
 - Criteria for initiation of AAT augmentation therapy

The post-test scores, and self reported confidence regarding the management of patients with Alpha-1 Antitrypsin Deficiency, signifies a clear gap in knowledge and an unmet need among clinicians. It continues to be an important area for future educational programs.



Course Director

Franck Rahaghi, MD, MHS, FCCP

Director of Advanced Lung Disease Clinic Director, Pulmonary Hypertension Clinic Head of Alpha-1 Foundation Clinical Resource Center Chairman, Dept. of Pulmonary and Critical Care Cleveland Clinic Florida Weston, FL

Activity Planning Committee

Gregg Sherman, MD Michelle Frisch, MPH, CCMEP Sandy Bihlmeyer M.Ed Daniela Hiedra

Deborah Paschal, CRNP

Faculty

Franck Rahaghi, MD, MHS, FCCP

Director of Advanced Lung Disease Clinic Director, Pulmonary Hypertension Clinic Head of Alpha-1 Foundation Clinical Resource Center Chairman, Dept. of Pulmonary and Critical Care Cleveland Clinic Florida Weston, FL

Alanna E. Kendig, FNP-BC, CCRN

Nurse Practitioner

Pulmonary and Critical Care Medicine

Weill Cornell Medicine

New York, New York

Instructor of Practice, Nursing

College of Mount Saint Vincent

Riverdale, NY



Clinical Updates for Nurse Practitioners and Physician Assistants: 2019

Commercial Support

The Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 series of CME activities were supported through educational grants or donations from the following companies:

- Actelion Pharmaceuticals US, Inc
- Sanofi US
- Grifols
- Boehringer Ingelheim Pharmaceuticals, Inc.
- GlaxoSmithKline
- Ferring Pharmaceuticals, Inc.
- ✤ Genentech



Curriculum Overview

2 Accredited Live Regional Symposium:

September 7, 2019, October 19, 2019



Enduring CME eMonograph

Launch: December 25, 2019 | End: December 14, 2020

Available at: https://bit.ly/37ZYDsP




COURSE SUMMARY

Cost: Free Start Date: 12/15/2019 Expiration Date: 12/14/2020 Target Audience: Pulmonologists, Primary Care Physicians, Nurse Practitioners and Physician Assistants Format: Monograph Estimated Time To Complete CME Activity: 1.0 hour Credit(s): 1.0 AMA PRA Category 1 Credit(s)TM 1.0 AANP Contact Hour which includes 0.75 pharmacology hours Hardware/Software Requirements: Any web browser

1 Accredited Live Virtual Simulcast: October 19, 2019



Clinical Highlights eMonograph - eMonograph containing key teaching points from the CME Activity was distributed 1 week after the meeting to all attendees.





Franck Rahaghi, MD, MHS,

Learning Objectives

Discuss the pathophysiology of Alpha-1 antitrypsin deficiency (AATD) and its impact on chronic obstructive pulmonary disease (COPD) risk.



Interpret the clinical significance of laboratory test results for AATD.



Discuss treatment options for AATD and latest GOLD guideline recommendations.




Discuss strategies to enhance detection and treatment of AATD in clinical practice.




Levels of Evaluation

Consistent with the policies of the ACCME, NACE evaluates the effectiveness of all CME activities using a systematic process based on Moore's model. This outcome study reaches Level 5.









Level 1:Participation





2 cities: 245 attendees



1 Live Virtual Simulcast: 526 attendees

City	Date	Attendees
Orlando, FL	9/28/19	162
Anaheim, CA (Live & Simulcast)	10/19/19	83 + 526






Provide direct patient care



Level 1: Demographics and Patient Reach









Level 2: Satisfaction



99% rated the activity as excellent



99% indicated the activity improved their knowledge



97% stated that they learned new and useful strategies for patient care



91% said they would implement new strategies that they learned




100% said the program was fair-balanced and unbiased



Confidence Assessment


Please rate your confidence in your ability to integrate the assessment and management of AATD into the care of patients with COPD:(Learning Objective 1, 2, 3, and 4)






Knowledge Assessment

In patients with Alpha-1 antitrypsin deficiency (AATD), which of the following mechanisms contributes to breakdown of lung tissue? (Learning Objective 1)



Knowledge Assessment

On genetic testing for AATD, which of the following genotypes has the strongest predisposition for an increased risk of AATD? (Learning Objective 1 and 2)



Pre: 370

Post: 395 PCA: 187


NACE

Pre-Post Change406%Pre-PCA Change231%

Knowledge Assessment

According to current guidelines, which of the following groups should be screened










Competence Assessment

A 62-y/o woman presents with progressive dyspnea and productive cough. She has no smoking history. Workup identifies FEV1/FVC 0.50 and FEV1 40% predicted. Chest X-ray shows mild emphysema with basilar predominance. Other findings are WNL.


Based on this information, what might be an appropriate next step? (Learning Objective 2, 3, and 4)



Competence Assessment

A 51-y/o man who presents with progressive significant dyspnea is diagnosed with COPD on workup. He had one exacerbation and no hospitalizations. FEV1/FVC is 0.60 and FEV1 is 45% predicted. Testing for AAT deficiency identifies ZZ genotype and low serum AAT levels (7 μ M). He is a former smoker (10 pack-years, quit 20 years ago).


Based on this information, what might be an appropriate next step? (Learning Objective 2 and 3)



Practice Assessment

How often do you order one-time AAT testing for your patients with COPD?


(Learning Objective 1 and 2)





(4-week Post Assessment N=187)

Please select the specific areas of skills, or practice behaviors, you have improved regarding the screening, diagnosis and treatment of AATD since this CME activity. (Select all that apply.)





((4-week Post Assessment N=187)

What specific barriers have you encountered that may have prevented you from successfully implementing strategies for patients with AATD since this CME activity? (Select all that apply)





Participant Educational Gains


127% increased recognition of the mechanism by which AATD contributes to lung tissue breakdown

406% increased awareness of the AATD genotype most associated with an increased risk of COPD

189% increased recognition of the need to screen all patients with COPD for AAT Deficiency 36% increased competence in ordering appropriate quantitative and qualitative AAT tests for a patient with symptomatic COPD



Persistent Educational Gaps After 4 Weeks





Key Take-home Points

53% increased competence in recognizing appropriate patients for AAT augmentation therapy

Significantly increased confidence in the ability to integrate the assessment and management of AATD into the care of patients with COPD

After 4 weeks, participants reported the following improved skills regarding the screening, diagnosis and treatment of AATD: 62% disease state awareness,45% screening protocols, and 39% timely referrals

After 4 weeks, participants reported the following barriers regarding the screening, diagnosis and treatment of AATD: 44% insurance/financial issues, 41% lack of knowledge, and 40% medication costs

